» Articles » PMID: 36984562

Overview and New Insights into the Metabolic Syndrome: Risk Factors and Emerging Variables in the Development of Type 2 Diabetes and Cerebrocardiovascular Disease

Overview
Publisher MDPI
Specialty General Medicine
Date 2023 Mar 29
PMID 36984562
Authors
Affiliations
Soon will be listed here.
Abstract

Metabolic syndrome (MetS) is considered a metabolic disorder that has been steadily increasing globally and seems to parallel the increasing prevalence of obesity. It consists of a cluster of risk factors which traditionally includes obesity and hyperlipidemia, hyperinsulinemia, hypertension, and hyperglycemia. These four core risk factors are associated with insulin resistance (IR) and, importantly, the MetS is known to increase the risk for developing cerebrocardiovascular disease and type 2 diabetes mellitus. The MetS had its early origins in IR and syndrome X. It has undergone numerous name changes, with additional risk factors and variables being added over the years; however, it has remained as the MetS worldwide for the past three decades. This overview continues to add novel insights to the MetS and suggests that leptin resistance with hyperleptinemia, aberrant mitochondrial stress and reactive oxygen species (ROS), impaired folate-mediated one-carbon metabolism with hyperhomocysteinemia, vascular stiffening, microalbuminuria, and visceral adipose tissues extracellular vesicle exosomes be added to the list of associated variables. Notably, the role of a dysfunctional and activated endothelium and deficient nitric oxide bioavailability along with a dysfunctional and attenuated endothelial glycocalyx, vascular inflammation, systemic metainflammation, and the important role of ROS and reactive species interactome are discussed. With new insights and knowledge regarding the MetS comes the possibility of new findings through further research.

Citing Articles

Exploring the Role of Ki67 in the Liver of Diabetic Rats.

Ababneh S, Siyam A, Alqaraleh M, Al-Rawashde F, Abbas M, Ababneh S Mater Sociomed. 2025; 36(4):250-256.

PMID: 39963446 PMC: 11830229. DOI: 10.5455/msm.2024.36.250-256.


Second-Generation Antipsychotics Induce Metabolic Disruption in Adipose Tissue-Derived Mesenchymal Stem Cells Through an aPKC-Dependent Pathway.

Varalda M, Venetucci J, Nikaj H, Kankara C, Garro G, Keivan N Cells. 2025; 13(24.

PMID: 39768174 PMC: 11674800. DOI: 10.3390/cells13242084.


Neuropathy and the metabolic syndrome.

Piccolo N, Wiggers A, Koubek E, Feldman E eNeurologicalSci. 2024; 38():100542.

PMID: 39720105 PMC: 11664003. DOI: 10.1016/j.ensci.2024.100542.


Impact of high-fructose diet and metformin on histomorphological and molecular parameters of reproductive organs and vaginal microbiota of female rat.

Demirel M, Sumlu E, Ozercan I, Sahin K, Tuzcu M, Bay V Sci Rep. 2024; 14(1):27463.

PMID: 39523383 PMC: 11551161. DOI: 10.1038/s41598-024-76211-5.


Thymoquinone: A comprehensive review of its potential role as a monotherapy for metabolic syndrome.

Ibrahim K, Hudu S, Jega A, Taha A, Yusuf A, Usman D Iran J Basic Med Sci. 2024; 27(10):1214-1227.

PMID: 39229585 PMC: 11366942. DOI: 10.22038/ijbms.2024.77203.16693.


References
1.
Burgess K, Bennett C, Mosnier H, Kwatra N, Bethel F, Jadavji N . The Antioxidant Role of One-Carbon Metabolism on Stroke. Antioxidants (Basel). 2020; 9(11). PMC: 7698340. DOI: 10.3390/antiox9111141. View

2.
Simons L, Simons J, Friedlander Y, McCallum J . Is prediction of cardiovascular disease and all-cause mortality genuinely driven by the metabolic syndrome, and independently from its component variables? The Dubbo study. Heart Lung Circ. 2011; 20(4):214-9. DOI: 10.1016/j.hlc.2010.12.005. View

3.
Woo K, Chook P, Lolin Y, Sanderson J, Metreweli C, Celermajer D . Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol. 1999; 34(7):2002-6. DOI: 10.1016/s0735-1097(99)00469-6. View

4.
Jaikaran E, Clark A . Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. Biochim Biophys Acta. 2001; 1537(3):179-203. DOI: 10.1016/s0925-4439(01)00078-3. View

5.
Van Gaal L, Wauters M, Mertens I, Considine R, De Leeuw I . Clinical endocrinology of human leptin. Int J Obes Relat Metab Disord. 1999; 23 Suppl 1:29-36. DOI: 10.1038/sj.ijo.0800792. View